Clinical Trials
20 trialsNCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00090870 2018-07-12
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT01779167 2018-07-11
THRiL for WM
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00281827 2017-12-28
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT00971126 2016-05-04
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT00450008 2016-03-17
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00934739 2015-02-25
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
Phase 2/3 Terminated
NCT01537861 2015-01-26
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated
NCT00215943 2014-04-17
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Terminated
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00573391 2011-08-12
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
University of Arkansas
Phase 3 Terminated
NCT00193102 2011-05-03
Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00209014 2009-05-07
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Emory University
Phase 2 Terminated
NCT00644306 2008-03-26
IFM 01/01
Central Hospital, Nancy, France
Phase 3 Terminated